Albireo   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Gothenburg Sweden (2008)
Status: Acquired by Ipsen (2023)

Organization Overview

First Clinical Trial
2009
NCT01007123
First Marketed Drug
2021
odevixibat (BYLVAY)
First NDA Approval
2021
odevixibat (BYLVAY)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Albireo | ALBIREO

Active Ingredients

Marketed Drugs (1)

odevixibat (BYLVAY) (2021 NDA)

Drugs in Phase 3 Trials (4)

Key: Albireo (1) Acquired (3)

insulin glargine (toujeo) (7 trials)

insulin human (humulin) (10 trials)

insulin lispro (humalog) (12 trials)

odevixibat (BYLVAY) (12 trials)

Drugs in Phase 2 Trials (3)

a3907 (1 trial)

cholestyramine (questran) (2 trials)

elobixibat (3 trials)

Drugs in Phase 1 Trials (1)

Key: Albireo (0) Acquired (1)

glucagon (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alagille Syndrome (Phase 3)

Biliary Atresia (Phase 3)

Cholestasis (Phase 3)

Cholestasis, Intrahepatic (Phase 3)

Constipation (Phase 2)

Dyslipidemias (Phase 2)

Fibrosis (Phase 2)

Liver Cirrhosis (Phase 2)

Liver Cirrhosis, Biliary (Phase 2)

Liver Diseases (Phase 1)

Malabsorption Syndromes (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Pruritus (Phase 2)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 34
  • # of Trial APIs: 8